Nu Skin Enterprises (NUS) Slammed as Citron Says China Sales in Jeopardy on Violations
Tweet
Share
E-mail
Get Alerts NUS Hot Sheet
Join SI Premium – FREE
Nu Skin Enterprises Inc. (NYSE: NUS) has found itself the target of famed short-selling website Citron Research, and investor are already running for the hills.
Citron belieives Nu Skin Enterprises is violating "direct selling" rules in China, "and their entire Chinese business operation could be in jeopardy of seizure and other substantial risks."
"Nu Skin investors are exposed to the massive risk of its China operations coming to an abrupt halt due to violation of the PRC’s and Hong Kong pyramid sales laws. The consequences would be devastating," Citron concludes.
Shares of NUS are down 8.5 percent to $44.70 on the negative mention.
Citron belieives Nu Skin Enterprises is violating "direct selling" rules in China, "and their entire Chinese business operation could be in jeopardy of seizure and other substantial risks."
"Nu Skin investors are exposed to the massive risk of its China operations coming to an abrupt halt due to violation of the PRC’s and Hong Kong pyramid sales laws. The consequences would be devastating," Citron concludes.
Shares of NUS are down 8.5 percent to $44.70 on the negative mention.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Scorpion Capital says short Twist Biosciences
- Quantum Cyber rejects short-seller's offer to halt reports if lawsuit dropped
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
Create E-mail Alert Related Categories
Insiders' Blog, Trader TalkRelated Entities
Citron ResearchSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
